Evidence map›Paper›PMID 41965333›Full record

ArticleNature communications2026

LaMGen: LLM-based 3D molecular generation for multi-target drug design.

Qun Su, Qiaolin Gou, Hui Zhang, Jike Wang, Huiyong Sun, Renling Hu, Rui Qin, Huanxiang Liu, Tingjun Hou, Yu Kang

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qun Su *College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0009-0001-1297-6663
Qiaolin Gou *Faculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Hui ZhangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Jike WangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0002-8118-8572
Huiyong SunDepartment of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.ORCID http://orcid.org/0000-0002-7107-7481
Renling HuCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Rui QinCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0002-0185-7570
Huanxiang LiuFaculty of Applied Sciences, Macao Polytechnic University, Macao, China. hxliu@mpu.edu.mo.ORCID http://orcid.org/0000-0002-9284-3667
Tingjun HouCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. tingjunhou@zju.edu.cn.ORCID http://orcid.org/0000-0001-7227-2580
Yu KangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. yukang@zju.edu.cn.ORCID http://orcid.org/0000-0002-0999-8802

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82373791National Natural Science Foundation of China (National Science Foundation of China) U25D9022
6 · The paper itself

Abstract

Multi-target drugs hold great promise for treating complex diseases, yet existing methodologies predominantly rely on ligand-based approaches, which lack sufficient biological context and are often confined to specific target pairs, resulting in limited generalizability. Here, we introduce LaMGen, a general-purpose multi-target drug design framework powered by large language models (LLMs). Built on MTD2025, a dataset comprising over 600,000 quantum-accurate molecular conformations and 700,000 multi-target associations, LaMGen directly yields energy-favorable conformations with quantum-level accuracy. The framework integrates ESM-C protein embeddings, rotation-aware ligand tokens, and a TriCoupleAttention module to capture multi-level target-ligand interactions. Across independent benchmarks, LaMGen outperforms diffusion-based model across multiple properties, generating molecules in an average of 0.44 s, while preserving high conformational plausibility. Retrospective analyses demonstrate that LaMGen not only can reproduce molecules identical to known actives, but also consistently produces structurally novel candidates with conserved core scaffolds and superior binding affinities.

Indexed as

Drug DesignHumansLarge Language ModelsLigandsModels, MolecularMolecular ConformationLigands

Identifiers

PMID41965333
PMCPMC13246799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.